Better mouse models to speed treatments for cancers caused by mutant p53
Optimizing Syngeneic Mouse Models to Target Mutant p53
This project builds improved lab mouse models to help develop treatments for people whose cancers are driven by mutant p53, including those with Li‑Fraumeni syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11307091 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are making and refining immune‑compatible (syngeneic) mouse tumors that carry the same mutant p53 changes seen in many human cancers. They will use these mice to test drugs that aim to restore normal p53 function and to compare how well these models predict treatment responses. The work is meant to make preclinical testing more reliable so promising therapies move to human trials with better evidence. Ultimately the team will compare these models to other common cancer models to find which best mimics human disease.
Who could benefit from this research
Good fit: People with tumors that have mutant p53, and individuals with Li‑Fraumeni syndrome who are at high risk for p53‑driven cancers, would be the likely candidates for future trials informed by this work.
Not a fit: Patients whose cancers do not involve p53 mutations or who have noncancer conditions are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could speed up and improve preclinical testing so effective mutant p53‑targeting therapies reach patients sooner.
How similar studies have performed: Related small molecules that aim to reactivate mutant p53 have shown promise in laboratory studies and early‑phase trials, but none are yet FDA approved, so this builds on partly tested approaches.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Li, Yong — Baylor College of Medicine
- Study coordinator: Li, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.